RESPONSE SURFACE METHODOLOGY-AIDED DEVELOPMENT OF PIRFENIDONE-LOADED SOLID LIPID NANOPARTICLES FOR INTRAPULMONARY DRUG DELIVERY SYSTEM

KEVIN KWOK; GATOT SUHARIYONO; SILVIA SURINI

doi:10.22159/ijap.2024v16i4.50231

Authors

KEVIN KWOK Laboratory of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia https://orcid.org/0009-0003-6700-3724
GATOT SUHARIYONO Nuclear Metrology and Quality Safety Technology Research Center – Nuclear Power Research Organization, National Research and Innovation Agency, South Tangerang, Indonesia https://orcid.org/0000-0003-0274-2940
SILVIA SURINI Laboratory of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia https://orcid.org/0000-0003-1211-9706

DOI:

https://doi.org/10.22159/ijap.2024v16i4.50231

Keywords:

Pirfenidone, Lipid nanoparticles, Formula optimization, Mass median aerodynamic diameter, Box-behnken design

Abstract

Objective: This study aims to determine the optimized Pirfenidone-loaded Solid Lipid Nanoparticles (P-SLN) formula for Intrapulmonary Drug Delivery System (IPDDS) using Response Surface Methodology (RSM).

Methods: Box-Behnken Design was applied to create fifteen P-SLN formulas comprising three independent variables, namely lipid-to-drug ratio, polymer type, and polymer concentration and three dependent variables, including particle size, Polydispersity Index (PDI), and entrapment efficiency. The P-SLNs were prepared by solvent injection followed by the ultrasonication method. Those formulas were optimized with the RSM approach using the Design Expert^®. Then, the optimized P-SLN was further characterized for morphology, moisture content, aerodynamic performance, and dissolution profile.

Results: The optimization process, assisted by RSM, determined that the optimized P-SLN had a lipid-to-drug ratio of 6:1 and contained 0.5% Plasdone K-29/32. The resulting P-SLN had a spherical shape with a particle size of 212.7 nm, a PDI of 0.39, an entrapment efficiency of 95.02%, and a low moisture content of 1.59%. The optimized P-SLN also exhibited appropriate IPDDS required characteristics, including a Mass Median Aerodynamic Diameter (MMAD) ranging from 0.540–12.122 μm and a Respirable Fraction (RF) of 12.4%. Moreover, the release of pirfenidone from this optimized formula was 89.61% and 69.28% in pH 4.5 and 7.4 buffer media, respectively, in 45 minutes through a combination of diffusion and polymer swelling mechanisms.

Conclusion: The optimized P-SLN showed promising potential as an IPDDS for pirfenidone.

Downloads

Download data is not yet available.

References

Ruwanpura SM, Thomas BJ, Bardin PG. Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease. Am J Respir Cell Mol Biol. 2020;62(4):413–22.

Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU. Idiopathic pulmonary fibrosis. Nat Rev Dis Prim. 2017;3(17074):1–19.

Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–32.

Zhou X, Yang D, Kong X, Wei C, LvQiu S, Wang L, Lin Y, Yin Z, Zhou Z, Luo H. Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis. Front Med. 2022;9(925703):1–7.

Seto Y, Inoue R, Kato M, Yamada S, Onoue S. Photosafety assessments on pirfenidone: Photochemical, photobiological, and pharmacokinetic characterization. J Photochem Photobiol B Biol. 2013;120(2013):44–51.

Park JH, Jin HE, Kim DD, Chung SJ, Shim WS, Shim CK. Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation. Int J Pharm. 2013;441(2013):562–9.

Gulati N, Chellappan DK, MacLoughlin R, Dua K, Dureja H. Inhaled nano-based therapeutics for inflammatory lung diseases: Recent advances and future prospects. Life Sci. 2021;285(119969):1–10. doi: 10.1016/j.lfs.2021.119969.

Abdelaziz HM, Gaber M, Abd-Elwakil MM, Mabrouk MT, Elgohary MM, Kamel NM, Kabary DM, Freag MS, Samaha MW, Mortada SM, Elkhodairy KA, Fang JY, Elzoghby AO. Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates. J Control Release. 2018;269(2018):374–92.

Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, Siva Kumar N, Vekariya RL. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC Adv. 2020;10(45):26777–91.

Anggraini R, Surini S, Saputri FC. Formulation and characterization of bitter melon extract (Momordica charantia) loaded phytosomes. Pharmacogn J. 2021;13(6):1347–54.

Duong VA, Nguyen TTL, Maeng HJ. Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules. 2020;25(20):1–36.

Zhao Y, Chang YX, Hu X, Liu CY, Quan LH, Liao YH. Solid lipid nanoparticles for sustained pulmonary delivery of Yuxingcao essential oil: Preparation, characterization and in vivo evaluation. Int J Pharm. 2017;516(1–2):364–71.

Ebrahimi HA, Javadzadeh Y, Hamidi M, Jalali MB. Repaglinide-loaded solid lipid nanoparticles: Effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles. DARU, J Pharm Sci. 2015;23(1).

Lamidi S, Olaleye N, Bankole Y, Obalola A, Aribike E, Adigun I. Applications of Response Surface Methodology (RSM) in Product Design, Development and Process Optimization. In: Kayaroganam P, editor. Response Surface Methodology - Research and Applications. Intechopen; 2023. doi: 10.5772/intechopen.106763.

Kumar R, Reji M. Response surface methodology (RSM): An overview to analyze multivariate data. Indian J Microbiol Res. 2023;9(4):241–8.

Parmar VK, Desai SB, Vaja T. RP-HPLC and UV Spectrophotometric Methods for Estimation of Pirfenidone in Pharmaceutical Formulations. Indian J Pharm Sci. 2014;76(3):225–9.

Hasyyati US, Surini S, Suhariyono G. Prospective pulmonary drug delivery system of pirfenidone microparticles for pulmonary fibrosis. J Appl Pharm Sci. 2023;0(00):1–11.

Surini S, Providya R, Putri KSS. Formula optimization of Rifampicin dry powder inhalation with chitosan-xanthan carrier using response surface methodology. J Appl Pharm Sci. 2019;9(1):33–41.

Abdo RW, Saadi N, Hijazi NI, Suleiman YA. Quality control and testing evaluation of pharmaceutical aerosols. In: Drug Delivery Systems. Netherland: Elsevier; 2019. p. 579–614.

Maboos M, Yousuf RI, Shoaib MH, Nasiri I, Hussain T, Ahmed HF, Iffat W. Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets. Lipids Health Dis. 2018;17(1):1–17.

Kumar JA, Bhikshapathi DVRN. Development of Nilotinib Loaded Solid Lipid Nanoparticles and Optimization By Central Composite Design Approach. Int J Appl Pharm. 2022;14(2):172–80.

Farsani PA, Mahjub R, Mohammadi M, Oliaei SS, Mahboobian MM. Development of Perphenazine-Loaded Solid Lipid Nanoparticles: Statistical Optimization and Cytotoxicity Studies. Biomed Res Int. 2021;2021(6619195):1–14.

He Y, Guo F. Micromechanical analysis on the compaction of tetrahedral particles. Chem Eng Res Des. 2018;136:610–9.

Putri KSS, Ramadhani LS, Rachel T, Suhariyono G, Surini S. Promising chitosan-alginate combination for rifampicin dry powder inhaler to target active and latent tuberculosis. J Appl Pharm Sci. 2022;12(5):098–103.

Chaurasiya B, Zhao YY. Dry powder for pulmonary delivery: A comprehensive review. Vol. 13, Pharmaceutics. MDPI AG; 2021. p. 1–28.

Hirota K, Hasegawa T, Nakajima T, Inagawa H, Kohchi C, Soma GI, Makino K, Terada H. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release. 2010;142(3):339–46.

Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):600–12.

Dudhat K, Patel H. Preparation and evaluation of pirfenidone loaded chitosan nanoparticles pulmonary delivery for idiopathic pulmonary fibrosis. Futur J Pharm Sci. 2022;8(1):1–14.

Ahmad I, Pandit J, Sultana Y, Mishra AK, Hazari PP, Aqil M. Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study. Mater Sci Eng C. 2019;100(2019):959–70.

Parvathaneni V, Kulkarni NS, Shukla SK, Farrales PT, Kunda NK, Muth A, Gupta V. Systematic development and optimization of inhalable pirfenidone liposomes for non-small cell lung cancer treatment. Pharmaceutics. 2020;12(3).

Rastogi V, Yadav P, Husain A, Verma A. Effect of hydrophilic and hydrophobic polymers on permeation of S-amlodipine besylate through intercalated polymeric transdermal matrix: 3(2) designing, optimization and characterization. Drug Dev Ind Pharm. 2019;45(4):669–82. doi: 10.1080/03639045.2019.1569035.

Aulia S, Winarti L, Wicaksono Y. Meloxicam Self-Nanoemulsifying Drug Delivery System: Formulation and Release Kinetics Analysis. Int J Appl Pharm. 2021;13(Special Issue 4):188–93.

Hu L, Kong D, Hu Q, Gao N, Pang S. Evaluation of High-Performance Curcumin Nanocrystals for Pulmonary Drug Delivery Both In Vitro and In Vivo. Nanoscale Res Lett. 2015;10(1):1–9. doi: 10.1186/s11671-015-1085-y.